Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05006131 · ClinicalTrials.gov registry record
Pancreatic Cancer Screening for At-risk Individuals
A clinical trial of Pancreatic Cancer, Adult, sponsored by Beth Israel Deaconess Medical Center.
- Recruiting
- Registry status
- 1,395
- Enrollment target
- 1
- Study location
NCT05006131 is a study of Pancreatic Cancer, Adult that is actively recruiting participants, run by Beth Israel Deaconess Medical Center. The registered enrollment target is 1,395 participants, above the 46-participant average among 3 other Pancreatic Cancer, Adult trials with a reported enrollment target (2933% higher). The trial reports 1 study location across 1 state.
The verdict
NCT05006131, a study of Pancreatic Cancer, Adult, is actively recruiting participants, sponsored by Beth Israel Deaconess Medical Center.
- RECRUITING
- Registry status
- 1,395 participants
- Enrollment target
- 1
- Study location
Study Summary
The investigators' goal is to conduct a prospective multicenter study to evaluate the yield and outcomes of screening of pancreas cancer in individuals who are at-risk for pancreatic cancer. We plan to use International Cancer of the Pancreas Screening (CAPS3) Consortium recommendations to standardize study population, screening methodology, and study outcomes.
Conditions Studied
Interventions
- OTHER Screening for pancreatic cancer
Study Locations (1)
Massachusetts
- Beth Israel Deaconess Medical Center - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,395 participants |
| Start Date | 2020-07-10 |
| Est. Completion | 2032-12-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05006131
The ClinicalTrials.gov registry entry for NCT05006131 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 1,395 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 46-participant average among 3 other Pancreatic Cancer, Adult trials with a reported enrollment target (2933% higher). The listed sponsor is Beth Israel Deaconess Medical Center, which has 488 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pancreatic Cancer, Adult appearing as the primary indexed condition, and to 1 intervention - of which Screening for pancreatic cancer is the first listed.
NCT05006131 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05006131 about?
NCT05006131 is a clinical study titled "Pancreatic Cancer Screening for At-risk Individuals". The investigators' goal is to conduct a prospective multicenter study to evaluate the yield and outcomes of screening of pancreas cancer in individuals who are at-risk for pancreatic cancer. We plan to use International Cancer of the Pancreas Screening (CAPS3) Consortium recommendations to standardi...
What is the current status of trial NCT05006131?
This trial is currently recruiting. The enrollment target is 1,395 participants. The study started on 2020-07-10. Estimated completion is 2032-12-31.
What conditions does trial NCT05006131 study?
This clinical trial studies the following conditions: Pancreatic Cancer, Adult.
What interventions are being tested in trial NCT05006131?
The interventions under investigation include: Screening for pancreatic cancer (OTHER).
Who is sponsoring clinical trial NCT05006131?
This trial is sponsored by Beth Israel Deaconess Medical Center, which has 488 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05006131 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Cancer, Adult
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer
RECRUITING · Phase 2
-
Trial to Evaluate Safety and Tolerability of GP-2250 in Combination With Gemcitabine
ACTIVE NOT RECRUITING · Phase 1
-
Trial Comparing EUS-guided Radiofrequency Ablation vs. EUS-guided Celiac Plexus Neurolysis
COMPLETED · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.